We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+118.15%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$307M
AUM Growth
+$109M
Cap. Flow
-$8.02M
Cap. Flow %
-2.62%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
3
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
AGRX
Agile Therapeutics
AGRX
+$7.12M
2
ZSAN
Zosano Pharma Corporation
ZSAN
+$2.46M
3
ANTH
Anthera Pharmaceuticals, Inc.
ANTH
+$2.4M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$1.11M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$13.8M
2
IMDZ
Immune Design Corp.
IMDZ
+$7.35M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$200M 65.32%
4,780,188
+39,001
+0.8% +$1.11M
IMDZ
2
DELISTED
Immune Design Corp.
IMDZ
$51M 16.62%
2,414,040
-281,717
-10% -$7.35M
AGRX
3
DELISTED
Agile Therapeutics
AGRX
$43.3M 14.12%
2,334
+406
+21% +$7.12M
ANTH
4
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$8.49M 2.77%
237,500
+81,250
+52% +$2.4M
ZSAN
5
DELISTED
Zosano Pharma Corporation
ZSAN
$2.32M 0.76%
+328
New +$2.46M
SVRA icon
6
Savara
SVRA
$1.08B
$1.24M 0.4%
36,455
– –
ACHN
7
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,122,957
Closed -$13.8M

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q1 2015 Portfolio in Review

As of Q1 2015, ProQuest Associates IV held 7 positions worth $307M, up 55% from $197M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV's Q1 2015 filing shows 1 new, 3 increased, 1 reduced and 1 closed positions. Its largest new stake was Zosano Pharma Corporation: 328 shares worth $2.32M. The largest sale was Achillion Pharmaceuticals, an estimated $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's largest Q1 2015 buy was Zosano Pharma Corporation: 328 shares worth $2.32M.
  • ProQuest Associates IV added most to Agile Therapeutics in Q1 2015, an estimated $7.12M increase.
  • ProQuest Associates IV's biggest Q1 2015 reduction was Immune Design Corp., cutting an estimated $7.35M.
  • ProQuest Associates IV fully exited Achillion Pharmaceuticals in Q1 2015, selling an estimated $13.8M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $307M portfolio in Q1 2015.
  • ProQuest Associates IV opened 1 new position and closed 1 in Q1 2015.
  • ProQuest Associates IV's portfolio value rose 55% quarter-over-quarter to $307M.

Based on ProQuest Associates IV's 13F filing for Q1 2015, filed 15 May 2015.